What Nimble Therapeutics does

Nimble Therapeutics is a preclinical-stage biotechnology company founded in 2019 and headquartered in Madison, Wisconsin, that specialized in developing oral peptide therapeutics for autoimmune diseases. The company built its strategy around a proprietary peptide synthesis and optimization platform designed to enable oral delivery of peptide-based drugs, which historically face bioavailability and stability challenges limiting them to injectable administration. Its lead preclinical asset was an oral peptide IL23R inhibitor intended to treat psoriasis and inflammatory bowel disease by targeting the IL-23 receptor pathway, a validated mechanism in immunology currently dominated by injectable biologics.

The company operated as an R&D-focused biotech with 11-50 employees and no commercial products, generating no revenue prior to its exit. Nimble was funded through a $10 million early-stage round in April 2019 led by Telegraph Hill Partners and was led by CEO Jigar Patel alongside CSO Pete Gough, CBO Cyrus Arman, and VP of Corporate Development Brad Garcia. In December 2024 AbbVie announced a definitive agreement to acquire Nimble for $200 million in cash at closing plus potential milestone payments, and the transaction closed in January 2025. Following the acquisition, Nimble ceased operating as an independent entity and its platform and IL23R inhibitor program were absorbed into AbbVie's immunology pipeline for continued development.

Name

Nimble Therapeutics

Website

https://nimbletherapeutics.com

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

11–50 employees

Short description

Nimble Therapeutics is a preclinical-stage biotech that developed oral peptide therapeutics for autoimmune diseases, including a lead IL23R inhibitor for psoriasis and inflammatory bowel disease, using a proprietary peptide synthesis platform. The company was acquired by AbbVie in January 2025.

Ownership category

akta.pro rank

Headquarters

HQ city

Madison

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations

Core offering

Nimble Therapeutics is a preclinical-stage biotech company that develops oral peptide therapeutics for autoimmune diseases, anchored by a proprietary peptide synthesis and optimization platform. Its lead asset is an investigational oral peptide IL23R inhibitor targeting psoriasis and inflammatory bowel disease, designed to offer improved patient compliance over injectable biologics.

Product overview

Nimble Therapeutics is a biotech company specializing in oral peptide therapeutics. The company developed a lead oral peptide IL23R inhibitor targeting psoriasis and inflammatory bowel disease, supported by its proprietary peptide synthesis and optimization platform. Both the lead asset and the technology platform were acquired by AbbVie in January 2025 for $200 million in cash plus potential milestone payments.

Differentiator

Problem solved

Functional benefit

Products and services

• Lead Oral Peptide IL23R Inhibitor An investigational, preclinical-stage oral peptide therapeutic targeting the IL-23 receptor pathway for the treatment of psoriasis and inflammatory bowel disease, designed to offer an oral alternative to injectable biologics.
• Proprietary Peptide Synthesis and Optimization Platform A proprietary technology platform used by Nimble Therapeutics for the synthesis and optimization of oral peptide therapeutics, enabling development of peptide drugs with improved oral bioavailability versus traditional injectable peptides.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators1 record

Recent moves3 records

Expansion highlights2 records

Direct peers

• Protagonist Therapeutics: Protagonist Therapeutics is a clinical-stage biotech developing oral peptide therapeutics, including assets in autoimmune and inflammatory diseases. It is the most direct peer to Nimble, sharing both the oral peptide modality and the autoimmune disease focus, with the key distinction that Protagonist's lead candidates (e.g., rusfertide, PN-881) are further advanced clinically.
• Bicycle Therapeutics: Bicycle Therapeutics develops synthetic bicyclic peptides (Bicycles) as targeted therapeutics, including T-cell engagers for oncology and other indications. While focused on oncology rather than autoimmune disease, Bicycle is a direct technology peer in synthetic constrained peptide drug discovery, sharing the modality philosophy of computationally designed peptides for difficult targets.
• Zealand Pharma: Zealand Pharma is a Danish biotech specializing in peptide-based therapeutics across metabolic and rare disease indications. It shares Nimble's peptide modality focus and platform-driven approach to discovering novel therapeutic peptides, and has commercial-stage peptide products, making it both a peer and a potential acquirer of similar platforms.
• Entera Bio: Entera Bio develops oral formulations of peptide and protein therapeutics, with a lead oral PTH program for hypoparathyroidism. It is directly comparable to Nimble's mission of making injectable biologics available as oral peptides, though Entera focuses on formulation-based oral delivery rather than novel peptide chemistry.

Emerging players

• PepGen: PepGen is a clinical-stage biotech developing peptide therapeutics enhanced with its proprietary Enhanced Delivery Oligonucleotide (EDO) conjugation technology for neuromuscular diseases. It is comparable to Nimble as a peptide platform company tackling hard-to-deliver peptide and oligonucleotide therapeutics, though PepGen's disease focus differs.
• Morphic Holding: Morphic Holding develops oral small molecule integrin inhibitors for autoimmune diseases including inflammatory bowel disease. While mechanistically distinct (small molecules vs. peptides), Morphic shares Nimble's strategy of pursuing oral therapies for autoimmune indications historically dominated by injectable biologics, and represents a comparable approach to patient-friendly oral immunology drugs.

Broad incumbents

• AbbVie: AbbVie is Nimble's acquirer and a global pharmaceutical leader with deep immunology franchise including Skyrizi (risankizumab, an IL-23 antibody) and Rinvoq (JAK inhibitor). It is a broad incumbent peer sharing Nimble's IL-23 pathway and autoimmune disease focus, and its strategic interest validates the platform approach.
• Eli Lilly: Eli Lilly markets Omvoh (mirikizumab), an IL-23 antibody approved for ulcerative colitis and Crohn's disease, and is developing other immunology assets. Lilly is a broad incumbent peer in the IL-23 autoimmune space and represents a potential competitive threat or strategic acquirer for similar oral peptide programs targeting psoriasis and IBD.
• Johnson & Johnson: Johnson & Johnson markets Tremfya (guselkumab), an IL-23 antibody for psoriasis and IBD, and is a major immunology player. J&J is a broad incumbent peer in the same IL-23/autoimmune space where Nimble's lead asset competes, with both established IL-23 franchise and active business development in immunology.
• Amgen: Amgen is a major biotech with established inflammation and immunology franchises, including Otezla for psoriasis/psoriatic arthritis. While Amgen does not currently market an IL-23 antibody, it is a broad incumbent peer in autoimmune disease therapeutics and a potential strategic acquirer of oral peptide platforms in this space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks3 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nimble Therapeutics